Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Ribi

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Journal of Cancer Survivorship : Research and Practice|June 10, 2022
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and SwitzerlandKarin Ribi, Eleonora Pagan, Isabella Sala, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2025
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trialMatthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, et al.
Annals of Surgical Oncology|June 28, 2018
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III TrialWalter Paul Weber, Christoph Tausch, Stefanie Hayoz, et al.
Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy TrialsPoornima Saha, Meredith M Regan, Olivia Pagani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.
British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
The Lancet. Oncology|November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Weixiu Luo, Per Karlsson, et al.
Cancer|September 23, 2025
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTKarin Ribi, Bernard F Cole, Gini F Fleming, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Journal of Cancer Survivorship : Research and Practice|June 10, 2022
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and SwitzerlandKarin Ribi, Eleonora Pagan, Isabella Sala, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2025
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trialMatthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, et al.
Annals of Surgical Oncology|June 28, 2018
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III TrialWalter Paul Weber, Christoph Tausch, Stefanie Hayoz, et al.
Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy TrialsPoornima Saha, Meredith M Regan, Olivia Pagani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.
British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
The Lancet. Oncology|November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Weixiu Luo, Per Karlsson, et al.
Cancer|September 23, 2025
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTKarin Ribi, Bernard F Cole, Gini F Fleming, et al.
Pageof 9